Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial

Am Heart J. 2021 Mar:233:1-4. doi: 10.1016/j.ahj.2020.11.003. Epub 2020 Nov 24.

Abstract

Recognizing that body surface area (BSA) is a commonly used metric to inform medication dosing across fields of medicine, it is possible that patients with heart failure with reduced ejection fraction (HFrEF) with higher BSA may be more likely to tolerate higher doses of GDMT. Using the HF-ACTION trial, we examined (1) the relationship between BSA and achievement of target dosing of evidence-based beta-blocker and angiotensin-converting enzyme inhibitor (ACEI) therapy, and (2) the associations and interactions between target dosing, clinical outcomes, and BSA.

MeSH terms

  • Adrenergic beta-Antagonists / administration & dosage*
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage*
  • Body Surface Area*
  • Cause of Death
  • Drug Dosage Calculations
  • Female
  • Heart Failure / drug therapy*
  • Heart Failure / mortality
  • Heart Failure / physiopathology
  • Humans
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Stroke Volume

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors